Análise comparativa do efeito de resposta ao tratamento da Hepatite C entre o interferon peguilado e interferon-alfa associados à ribavirina em pacientes do HSE-RJ

• Ano de defesa: 2013
• Autor(a) principal: Melo, Luciana Oliveira de Rezende
• Orientador(a): Rodrigues, Nádia Cristina Pinheiro
• Banca de defesa: Monteiro, Denise Leite Maia , Cavalini, Luciana Tricai , Sabra, Aderbal Magno Caminada , Pereira, Sandra de Morais
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade do Estado do Rio de Janeiro
• Programa de Pós-Graduação: Programa de Pós-Graduação em Ciências Médicas
• Departamento: Centro Biomédico::Faculdade de Ciências Médicas
• País: BR
• Palavras-chave em Português: Hepatite C; Tratamento; Interferons; Ribavirina; Fatores de Risco; Hepatite C Tratamento; Interferon; Interferon alfa; Saúde pública; Fatores de risco
• Palavras-chave em Inglês: Hepatitis C; Treatment; Interferons; Ribavirin; Risk Factors
• Área do conhecimento CNPq: CNPQ::CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::GASTROENTEROLOGIA
• Link de acesso: http://www.bdtd.uerj.br/handle/1/8584

Hepatitis C (HC) is a serious public health problem worldwide. According to estimates by the World Health Organization, about 3% of the world population is infected with hepatits C virus. The objective of treatment of HC is avoid the progression of liver disease by inhibition of viral replication. The aim of this study was to compare the effect of treatment response of hepatitis C between pegylated interferon (PEGINF) + ribavirin (RBV) and interferon-alpha (INF) + ribavirin (RBV) and evaluate the relationship of risk factors, age, gender, genotype, degree of fibrosis, treatment time and comorbidities. We conducted a retrospective study of medical records of patients seen at the clinic of Hepatology, Servants Hospital of the State of Rio de Janeiro (HSE), 2001 to 2009. Data were analyzed using bivariate and multivariate analyzes (logistic regression). About 85% of patients treated for 48 weeks, and 15% of those treated for 24 weeks had sustained virologic response (SVR) positive. About 65% of patients receiving PEGINF + RBV and 35% of those who received INF + RBV had positive RVS. In relation to treatment interruption, the association between the degree of liver fibrosis and the probability of remaining treatment was statistically significant . The risk of interruption is six times higher with more advanced fibrosis degree (F4) than compared to the less advanced fibrosis degree (F2). The risk of stopping treatment after the first 24 weeks for patients with genotype 3 was 2.5 times higher than those patients with genotype 1.